MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tauopathies"

  • 2017 International Congress

    Tyrosine kinase inhibition clears Tau and reserves neuropathology and motor symptoms in a novel model of progressive supranuclear palsy

    Y. Torres-Yaghi, F. Pagan, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, M. Javidnia, M. Hebron, C. Moussa (Washington, DC, USA)

    Objective: Our objective was to examine the effects of tau accumulation in transgenic mice, observing both motor function and behavior.  Background: Tau hyper-phosphorylation is a…
  • 2017 International Congress

    Freezing of gait is an early clinical feature of progressive supranuclear palsy

    Y. Osaki, Y. Morita, Y. Miyamoto, T. Furushima, K. Furuta, H. Furuya (Nankoku, Japan)

    Objective: We attempted to identify any sign or symptom to diagnose progressive supranuclear palsy (PSP) earlier. Background: Early clinical diagnosis of progressive supranuclear palsy PSP…
  • 2017 International Congress

    Tau Network Genes in a Genome Wide Association Study of Progressive Supranuclear Palsy

    T. Chang (Los Angeles, CA, USA)

    Objective: To determine how tau network genes overlap with single nucleotide polymorphisms (SNPs) associated with Progressive Supranuclear Palsy (PSP) in a Genome Wide Association Study…
  • 2016 International Congress

    High throughput pooled-DNA sequencing of mendelian/susceptibility Parkinson’s disease genes in Spanish population

    S. Ortega-Cubero, O. Lorenzo-Betancor, E. Lorenzo, B.A. Benitez, C. Cruchaga, L. Samaranch, M. Diez, J.A. Obeso, M.C. Rodriguez-Oroz, M. Aguilar, M.A. Pastor, P. Pastor (Palencia, Spain)

    Objective: The primary outcome of our study was the identification of rare variants in 5 major Mendelian PD genes (SNCA, PARK2, PINK1, DJ1, LRRK2) and…
  • 2016 International Congress

    Phosphorylation by GSK-3β enhances binding of metal ion induced tau oligomers to neutral lipid surfaces

    G.S. Nuebling, E. Plesch, T. Högen, S. Lorenzl, F. Kamp, A. Giese (Munich, Germany)

    Objective: To dissect the complex interplay of tau hyperphosphorylation, metal ion induced oligomer formation and membrane interactions applying single particle fluorescence techniques. Background: Fibrillar deposits…
  • 2016 International Congress

    THK-5351 tau-tracer uptake in patients with clinically diagnosed progressive supranuclear palsy

    S. Schönecker, M. Brendel, J. Havla, G. Höglinger, K. Bötzel, A. Danek, A. Rominger, J. Levin (Munich, Germany)

    Objective: The objective of our study is to investigate characteristics of THK-5351 binding in patients with clinically diagnosed progressive supranuclear palsy (PSP) and correlate tau-tracer…
  • 2016 International Congress

    Tau PET in Parkinson syndromes. A new diagnostic tool?

    J. Hammes, G.N. Bischof, K. Giehl, Ö. Onur, A. Drzezga, T. Klockgether, T. van Eimeren (Cologne, Germany)

    Objective: To explore the potential of [F-18]-AV-1451 PET as a diagnostic tool in Parkinson plus syndromes. Background: Clinically, atypical Parkinson syndromes are often difficult to…
  • 2016 International Congress

    [18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease

    J.B. Rowe, P. Vázquez Rodríguez, Y.T. Hong, R.J. Borchert, S. Sami, W.R. Bevan-Jones, S.P. Jones, R. Arnold, A. Surendranathan, E. Mak, S. Li, T. Fryer, J. O'Brien, L. Passamonti (Cambridge, United Kingdom)

    Objective: To evaluate: (1) brain tau pathology in vivo in patients with Progressive Supranuclear Palsy (PSP) and Alzheimer's disease (AD); (2) whether brain tau pathology…
  • 2016 International Congress

    PET imaging of tau pathology in progressive supranuclear palsy

    S. Coakeley, S.S. Cho, P. Rusjan, A. Graff-Guerrero, R. Chen, A.E. Lang, L. Kalia, E. Slow, S. Houle, A.P. Strafella (Toronto, ON, Canada)

    Objective: This study aimed to determine whether there is an increase in [18F]-AV-1451 uptake in the brains of progressive supranuclear palsy (PSP) patients compared to…
  • 2016 International Congress

    Evaluation of the surface based measures to discriminate progressive supranuclear palsy from corticobasal syndrome

    N. Upadhyay, A. Suppa, M.C. Piattella, F.D. Stasio, C. Colonnese, C. Colosimo, A. Berardelli, P. Pantano (Rome, Italy)

    Objective: To evaluate structural gray matter (GM) changes tested by surface-based measures of cortical thickness (CTh), surface area (SA) and volume (VOL), in order to…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley